BioNTech Investor Day Presentation Deck

BNT312 Bispecific antibody designed to strengthen T cell and APC synapse Inert Fc, double conditional, dual CD40×4-1BB agonist D GEN1042 (BNT312) 4-1BB-expressing cell (eg, T cell) BNT311 binding affinity: KD CD40 1.0 nmol/L, 4-1 BB: 0.17 nmol/L Conditional 4-1BB agonist activity 4-1BB GEN1042 CD40 Conditional CD40 agonist activity CD40-expressing APC (eg, dendritic cell) APC maturation, Conditional CD40-stimulation of APC and conditional 4-1BB mediated stimulation of T cells T cell T cell Enhanced natural killer (NK) cell activity Expression of costimulatory molecules e.g. HLA-DR, CD86 Production of stimulatory cytokines GEN1042 Activated dendritic CD86/HLA-DR Tumor draining lymph node 4-1BB Tumor lysis CD40 Tumor 00 Granzyme Perforin Granzymes, perforins Activated coll Blood vessel Proliferation Activated T cell Differentiation Memory T cell Cytokines TCR-MHC receptors Tumor lysis Enhanced effector T cell activity Cytokines Y T cell proliferation and differentiation CD28/CD80 receptors Protein therapeutics "Double-conditional" "dual-agonist" molecule for two preclinically validated targets: CD40: stimulatory receptor primarily expressed on APCs. Engagement of CD40 leads to activation and maturation of APC s 4-1BB: costimulatory tumor necrosis factor expressed on T-cells and NK-cells. Activating the 4-1BB pathway enhances T cell proliferation, T cell effector functions, and prevents T cell death Inert Fc to avoid unwanted immune cells crosslinking BNT312 (Gen1042) is partnered with Genmab based on 50/50 sharing of costs and profits; ¹ Muik A, et al. J Immunother Cancer 2022;0:e004322. doi:10.1136/jitc-2021-004322. BIONTECH 124

View entire presentation